

Exhibit G

WTS Number: 698304



Request Date: 7/20/11 9:17 AM

Conf Number: 220698

Requester: Timothy Jones

Sterne Kessler Goldstein & Fox

1100 New York Avenue, NW, Suite 900

Washington, DC 20005

Company Phone: 202-371-2600

Requester Phone: 202-772-8789

Fax: 202-371-2540

Requester Email: Tjones@skgf.com
Send-To Email: Tjones@skgf.com

Reference: 2286.0880000

RUSH

Delivery: Email

Instructions:

1. Nielsen LP; Mygind N-Drugs 61(11):pgs. 1563-79,2001

Med/270879


An outreach service of the Kurt F. Wendt Library, University of Wisconsin - Madison Email: wts@engr.wisc.edu | Web: http://www.wisc.edu/techsearch | Phone: (608) 262-5917

0012-6667

Requester assumes responsibility for copyright compliance.

Refer Off Campus







# Drugs

#### International Editorial Board

D.R. Abernethy, Baltimore, MD, USA S. Bank, New York, NY, USA P.J. Barnes, London, England P.N. Bennett, Bath, England W.M. Bennett, Portland, OR, USA G. Bianchi Porro, Milan, Italy W.R. Bowie, Vancouver, BC, Canada A.M. Breckenridge, Liverpool, England L. de Angelis, Trieste, Italy F.T. Fraunfelder, Portland, OR, USA E.D. Freis, Washington, DC, USA W.H. Frishman, Valhalla, NY, USA B.G. Gazzard, London, England D.C. Harrison, Cincinnati, OH, USA ED Hart, London, England E.C. Huskisson, London, England T. Itoh, Osaka, Japan G.D. Johnston, Belfast, N. Ireland M.H. Lader, London, England M.J.S. Langman, Birmingham, England H. Lode, Berlin, Germany A.P. MacGowan, Bristol, England H.I. Maibach, San Francisco, CA, USA F.H. McDowell, White Plains, NY, USA F.M. Muggia, New York, NY, USA K.G. Nober, Straubing, Germany S. Nattel, Montreal, PQ, Canada C.E. Nord, Huddinge, Sweden H. Pardell, Barcelona, Spain P. Patsalos, London, England R. Pauwels, Ghent, Belgium J.C. Petrie, Aberdeen, Scotland B.N.C. Prichard, London, England S.H. Roth, Phoenix, AZ, USA S. Shuster, Framlingham, England B.N. Singh, Los Angeles, CA, USA T.M. Speight, Auckland, New Zealand J.S. Turner, Gainesville, GA, USA J. Turnidge, Adelaide, SA, Australia J.A. Vale, Birmingham, England D.J. Zegarelli, New York, NY, USA

Aim and Scope: Drugs promotes optimum pharmacotherapy by providing a programme of review articles covering the most important aspects of clinical pharmacology and therapeutics.

The Journal includes:

- Leading/current opinion articles providing an overview of contentious or emerging issues
- Definitive reviews of drugs and drug classes and their place in disease management
- Therapy in Practice articles including recommendations for specific clinical situations
- Adis Drug Evaluations reviewing the properties and place in therapy of both newer and established drugs
- Adis New Drug Profiles with expert commentary.

All manuscripts are subject to peer review by international experts. Letters to the editor are welcomed and will be considered for publication.

Editor: Dene C. Peters

Publication Manager: Rebecca Vuetilovoni

**Editorial Office and Inquiries:** Adis International Ltd, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 10, New Zealand. Information on the preparation of manuscripts will be provided to authors.

E-mail: drugs@adis.co.nz

http://www.adis.com

Drugs (ISSN 0012-6667) is published by Adis International Limited. Annual 2001 subscription price: \$US1995; Japan ¥332 478. Annual subscription consists of 1 volume with 15 issues. Online only available for the same price as print subscription; print and online available for an additional 20%. (Further subscription information is given at the back of each issue.)

Policy Statement: Although great care has been taken in compiling the content of this publication, the publisher and its servants are not responsible or in any way liable for the currency of the information, for any errors, omissions or inaccuracies, or for any consequences arising therefrom. Inclusion or exclusion of any product does not imply its use is either advocated or rejected. Use of trade names is for product identification only and does not imply endorsement. Opinions expressed do not necessarily reflect the views of the Publisher, Editor or Editorial Board.

Copyright: © 2001 Adis International Ltd. All rights reserved throughout the world and in all languages. No part of this publication may be reproduced, transmitted or stored in any form or by any means either mechanical or electronic, including photocopying, recording, or through an information storage and retrieval system, without the written permission of the copyright holder.

The appearance of the code at the top of the first page of an article in this journal indicates the copyright owner's consent that copies of the article may be made for the personal or internal use of specific clients. This consent is given provided that the fee of \$US27.50 per copy is paid directly to the Copyright Clearance Center Inc., 222 Rosewood Drive, Danvers, Massachusetts 01923, USA, for copying beyond that permitted by sections 107 or 108 of the US Copyright Law. This consent does not extend to other kinds of copying such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale.

© Adis International Limited. All rights reserved

# Intranasal Corticosteroids for Allergic Rhinitis

### **Superior Relief?**

Lars Peter Nielsen, 1,2 Niels Mygind2 and Ronald Dahl2

- 1 Department of Clinical Pharmacology, University of Aarhus, Aarhus, Denmark
- 2 Department of Respiratory Diseases, Aarhus University Hospital, Aarhus, Denmark

### Contents

Ab	istract - 1
1	Antihistamines
	1,1 General Considerations
	1.2 Oral Antihistamines
	1,3 Topical Antihistamines
	1.4 Comparative Effect of Antihistamines
	1.4.1 Single Dose Studies
	1.4.2 Perennial Allergic Rhinitis
	1.4.3 Seasonal Allergic Rhinitis
	1.4.4 Studies in Children
	1.4.5 Topical vs Oral Antihistamines
	1.4.6 Safety
2.	Corticosteroids
	2.1 General Considerations
	2.2 Intranasal Corticosteroids
	2.3 Comparative Effect of Intranasal Corticosteroids 1568
	2.3.1 Perennial Allergic Rhinitis
	2.3.2 Seasonal Allergic Rhinitis
3.	2.3.3 Safety
J.	
	ord Control of Arminoral miles and milliand Control of
	3.4 Safety
	3.5 Cost Effectiveness 4
4,	Conclusion

### **Abstract**

Whether first-line pharmacological treatment of allergic rhinitis should be antihistamines or intranasal corticosteroids has been discussed for several years.

First-generation antihistamines are rarely used in the treatment of allergic rhinitis, mainly because of sedative and anticholinergic adverse effects. On the basis of clinical evidence of efficacy, no second-generation antihistamine seems preferable to another. Similarly, comparisons of topical and oral antihistamines





have been unable to demonstrate superior efficacy for one method of administration over the other.

Current data documents no striking differences in efficacy and safety parameters-between intranasal corticosteroids.

When the efficacy of antihistamines and intranasal corticosteroids are compared in patients with allergic rhinitis, present data favours intranasal corticosteroids. Interestingly, data do not show antihistamines as superior for the treatment of conjunctivitis. Safety data from comparative studies in patients with allergic rhinitis do not indicate differences between antihistamines and intranasal corticosteroids. Combining antihistamines and intranasal corticosteroids in the treatment of allergic rhinitis does not provide any additional effect to intranasal corticosteroids alone. On the basis of current data, intranasal corticosteroids seem to offer superior relief in allergic rhinitis than antihistamines.

Allergic rhinitis is a common condition elicited by an immunoglobulin (Ig)E-mediated allergic inflammation of the nasal mucosa and characterised by nasal obstruction, rhinorrhoea, sneezing and nasal itch, and often accompanied by conjunctivitis. It is present in 10 to 20% of the population in industrialised countries. [1] Moreover, this prevalence seems to be increasing. [2,3] Although allergic rhinitis is not a life-threatening disease, it can severely impact on quality of life [4-6] and be associated with comorbidity from other diseases, for example, asthma and conjunctivitis. [7]

Treatment of allergic rhinitis consists of allergen avoidance, allergen-specific immunotherapy and pharmacological intervention, of which the former two lie beyond the scope of the present review. Two mainstream options have evolved for pharmacological treatment, antihistamines and topical corticosteroids. The choice between these options has been extensively discussed since the introduction of intranasal corticosteroid treatment.<sup>[8]</sup>

This review considers first-line pharmacological treatment of allergic rhinitis and will deal only with antihistamines and intranasal corticosteroids (INCS), as we consider cromones, anticholinergics, leukotriene modifiers, decongestants and systemic corticosteroids as secondary treatment options in allergic rhinitis.

Only data obtained in patients with allergic rhinitis have been considered for the comparative evidence presented in this review.

### 1. Antihistamines

#### 1.1 General Considerations

Histamine is the major pathophysiological mediator of allergic rhinitis. Its role is almost exclusively mediated through the histamine H<sub>1</sub>-receptor, whereas the role of other histamine receptors in allergic rhinitis remains to be clarified. Thus, in the context of allergic rhinitis, antihistamines are H<sub>1</sub>receptor antagonists. [9,10] In addition to H1-receptor blockade, an anti-inflammatory effect of antihistamines has been proposed, as some of the newer compounds have been shown to influence cytokine production, mediator release and inflammatory cell flux.[11-19] However, other studies have been unable to confirm these findings.[20-23] Whether antihistamines offer a clinically beneficial anti-inflammatory effect in addition to inhibition of histamine remains a question to be answered.

#### 1.2 Oral Antihistamines

Numerous  $H_1$ -receptor antagonists have been developed. For oral use, these can be divided into older first-generation [e.g. chlorphenamine (chlorpheniramine), diphenhydramine, promethazine and triprolidine] and newer second-generation antihistamines (acrivastine, astemizole, cetirizine, ebastine, fexofenadine, loratadine, mizolastine and terfenadine). This review deals with the newer antihistamines as the use of the older drugs in allergic

© Adis International Limited. All rights reserved

Drugs 2001; 61 (11)



# DOCKET

# Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

### **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

### **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

### API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

### **LAW FIRMS**

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

### **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

### **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

